thymoglobulin + everolimus

Thymoglobulin + everolimus is a combination of two immunosuppressive agents used primarily in the context of organ transplantation to prevent rejection. - **Thymoglobulin** (antithymocyte globulin [rabbit]) is a polyclonal antibody preparation derived from rabbits immunized with human thymocytes. It acts by depleting T lymphocytes through multiple mechanisms including complement-dependent lysis and opsonization for phagocytosis. This results in profound immunosuppression and is commonly used for induction therapy or treatment of acute rejection episodes in transplant recipients[3]. - **Everolimus** is an mTOR (mammalian target of rapamycin) kinase inhibitor that binds to FKBP-12 to form a complex inhibiting mTORC1 activity. This leads to cell cycle arrest at the G1 phase and reduces cell proliferation and angiogenesis. Everolimus also suppresses immune responses by inhibiting T-cell activation and proliferation[1][2][5]. It is approved for use in various cancers as well as for prevention of organ transplant rejection when combined with other agents such as corticosteroids or calcineurin inhibitors[1][2][4].

Brand names

AfinitorZortressCerticanVotubiaTorpenz

Other names

antithymocyte globulin rabbitantithymocyte globulin [rabbit]RAD001RAD-001RAD 001